Filing Flows › Zevra Therapeutics (ZVRA) › Q2 2025
Zevra Therapeutics (ZVRA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Zevra Therapeutics (ZVRA) reported revenue of $25.9M for the second quarter 2025 (Q2 2025), +482% from a year earlier and +27% from the quarter before. Operating margin was -274.5%, net earnings $74.7M (288.7% of revenue).
Zevra Therapeutics, Q2 2025: revenue $25.9M (+482% year over year), operating margin -274.5%, net earnings $74.7M, operating cash flow −$3.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25.9M | +27% | +482% |
| Operating profit | −$71.0M | — | — |
| Net earnings | $74.7M | — | — |
| Operating cash flow | −$3.6M | — | — |
What changed
Revenue was $25.9M in Q2 2025, up 482% year over year and up 27% from the previous quarter.
Operating costs exceeded revenue by $71.0M, an operating margin of -274.5%. Total costs grew 243% against revenue growth of 482%. The fastest-growing cost line was Other operating costs (+3802%). Net earnings were $74.7M. The effective tax rate was 2.9%. Non-operating items added $147.9M, 192% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$3.6M. Non-cash charges added back $1.7M of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $82.4M. Capital expenditures of $213K exceeded it, leaving free cash flow of −$3.8M.
Questions
What was Zevra Therapeutics' revenue in the second quarter 2025?
Zevra Therapeutics (ZVRA) reported revenue of $25.9M for the second quarter 2025 (Q2 2025), +482% from a year earlier and +27% from the quarter before.
Was Zevra Therapeutics profitable in the second quarter 2025?
Operating loss was $71.0M (-274.5% of revenue) and net earnings $74.7M.
Source: Zevra Therapeutics 10-Q on SEC EDGAR.